18F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: The MUNICON II trial

Journal of Nuclear Medicine

Volumn 52, Issue 8, 2011, Pages 1189-1196

  Zum Büschenfelde, Christian Meyer ^a   Herrmann, Ken ^a   Schuster, Tibor ^a   Geinitz, Hans ^a   Langer, Rupert ^a   Becker, Karin ^a   Ott, Katja ^b   Ebert, Matthias ^a   Zimmermann, Frank ^a,c   Friess, Helmut ^a   Schwaiger, Markus ^a   Peschel, Christian ^a   Lordick, Florian ^a,d   Krause, Bernd Joachim ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Esophageal cancer; Oncology; PET; Predictive value; Response

Indexed keywords

CISPLATIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; PACLITAXEL;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CONTINUOUS INFUSION; DIARRHEA; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPHAGIA; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS RESECTION; FEMALE; HISTOPATHOLOGY; HUMAN; LOWER ESOPHAGUS SPHINCTER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SALVAGE THERAPY; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOTHERAPY, ADJUVANT; REMISSION INDUCTION; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 80051703750     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.085803     Document Type: Article

References (37)

1. Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet. 2002;359:1727-1733.
2. Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009;27:5062-5067.
3. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11-20.
4. Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 2007;8:226-234. (Pubitemid 46291702)
5. Boige V, Pignon J, Saint-Aubert B, et al. Final results of a randomized trial comparing preoperative 5-fluorouracil/cisplatin to surgery alone in adenocarcinoma of the stomach and lower oesophagus: FNLCC ACCORD 07-FFCD 9703 trial. J Clin Oncol. 2007;25(200s; abstr 4512).
6. Schuhmacher C, Schlag PM, Lordick F, et al. Neoadjuvant chemotherapy versus chemotherapy alone for locally advanced adenocarcinoma of the stomach and cardia. Final results of the EORTC phase III randomized trial 40954. J Clin Oncol. 2007;25(June 20 supplement):4510.
7. Ilson DH. Cancer of the gastroesophageal junction: combined modality therapy. Surg Oncol Clin N Am. 2006;15:803-824. (Pubitemid 44499029)
8. Kelsen DP, Winter KA, Gunderson LL, et al. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol. 2007;25:3719-3725. (Pubitemid 47372613)
9. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358:36-46.
10. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24:4991-4997. (Pubitemid 46631401)
11. Fareed KR, Kaye P, Soomro IN, et al. Biomarkers of response to therapy in oesophago-gastric cancer. Gut. 2009;58:127-143.
12. Ott K, Weber WA, Lordick F, et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol. 2006;24:4692-4698. (Pubitemid 46646244)
13. Weber WA, Ott K, Becker K, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol. 2001;19:3058-3065. (Pubitemid 32565444)
14. Lordick F, Ott K, Krause BJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol. 2007;8:797-805. (Pubitemid 47308659)
15. Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg. 1998;85:1457-1459. (Pubitemid 28502569)
16. Bartels H, Stein HJ, Schomig A, Siewert JR. Risk assessment [in German]. Chirurg. 1997;68:654-661.
17. Rosenberg R, Herrmann K, Gertler R, et al. The predictive value of metabolic response to preoperative radiochemotherapy in locally advanced rectal cancer measured by PET/CT. Int J Colorectal Dis. 2009;24:191-200.
18. Souvatzoglou M, Bengel F, Busch R, et al. Attenuation correction in cardiac PET/CT with three different CT protocols: a comparison with conventional PET. Eur J Nucl Med Mol Imaging. 2007;34:1991-2000. (Pubitemid 350212118)
19. Ott K, Bader FG, Lordick F, Feith M, Bartels H, Siewert JR. Surgical factors influence the outcome after Ivor-Lewis esophagectomy with intrathoracic anastomosis for adenocarcinoma of the esophagogastric junction: a consecutive series of 240 patients at an experienced center. Ann Surg Oncol. 2009;16:1017-1025.
20. Becker K, Mueller JD, Schulmacher C, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. 2003;98:1521-1530. (Pubitemid 37151509)
21. Sarbia M, Becker KF, Hofler H. Pathology of upper gastrointestinal malignancies. Semin Oncol. 2004;31:465-475. (Pubitemid 39070266)
22. Lordick F, Ruers T, Aust DE, et al. European Organisation of Research and Treatment of Cancer (EORTC) Gastrointestinal Group. Workshop on the role of metabolic imaging in the neoadjuvant treatment of gastrointestinal cancer. Eur J Cancer. 2008;44:1807-1819.
23. Krak NC, Boellaard R, Hoekstra OS, Twisk JW, Hoekstra CJ, Lammertsma AA. Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial. Eur J Nucl Med Mol Imaging. 2005;32:294-301. (Pubitemid 40562120)
24. Herrmann K, Bundschuh RA, Rosenberg R. Comparison of different SUV-based methods for response prediction to neoadjuvant radiochemotherapy in locally advanced rectal cancer by FDG-PET and MRI. Mol Imaging Biol. October 9, 2010 [Epub ahead of print].
25. 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol. 2003;21:428-432.
26. Flamen P, Van Cutsem E, Lerut A, et al. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol. 2002;13:361-368. (Pubitemid 34704995)
27. Javeri H, Xiao L, Rohren E, et al. The higher the decrease in the standardized uptake value of positron emission tomography after chemoradiation, the better the survival of patients with gastroesophageal adenocarcinoma. Cancer. 2009;115:5184-5192.
28. 18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer. Ann Surg. 2006;243:472-478.
29. Swisher SG, Erasmus J, Maish M, et al. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer. 2004;101:1776-1785. (Pubitemid 39314740)
30. 18F]- Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer. Ann Surg. 2009;250:888-894.
31. 18F-fluorodeoxyglucose- positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy. Eur J Cancer. 2007;43:1385-1391.
32. Fiorica F, Di Bona D, Schepis F, et al. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut. 2004;53:925-930. (Pubitemid 38824146)
33. Steyerberg EW, Neville BA, Koppert LB, et al. Surgical mortality in patients with esophageal cancer: development and validation of a simple risk score. J Clin Oncol. 2006;24:4277-4284. (Pubitemid 46630785)
34. Stahl M, Walz MK, Stuschke M, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009;27:851-856.
35. Rizk NP, Seshan VE, Bains MS, et al. Prognostic factors after combined modality treatment of squamous cell carcinoma of the esophagus. J Thorac Oncol. 2007;2:1117-1123. (Pubitemid 350307906)
36. Chirieac LR, Swisher SG, Ajani JA, et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer. 2005;103:1347-1355. (Pubitemid 40410728)
37. Langer R, Ott K, Feith M, Lordick F, Siewert JR, Becker K. Prognostic significance of histopathological tumor regression after neoadjuvant chemotherapy in esophageal adenocarcinomas. Mod Pathol. 2009;22:1555-1563.